胶囊内镜患者临床资料分析142例

Analysis of capsule endoscopy in clinical diagnosis (142 cases)

摘要:

目的   探讨胶囊内镜（CE）对小肠疾病的检出价值并评估其安全性。方法   回顾性分析142例行CE检查的患者临床资料，包括症状组124例和体检组18例。分析CE运行时间、肠道清洁度、病变检出情况和并发症发生情况，评估CE对小肠疾病的检出价值以及安全性。结果   142名患者均未出现误吞气管、胶囊滞留等并发症。CE平均运行时间498.3 min，胃35.6 min，小肠273.6 min。小肠疾病总体检出率为57.14%，症状组为59.68%，体检组为37.50%。症状组检出率明显高于体检组，两者比较差异有统计学意义（P <0.05）。在症状组中，CE对不明原因消化道出血、腹痛、腹泻、腹胀、消瘦/纳差、肿瘤标志物升高和排便异常患者的小肠病变检出率分别为78.38%、52.08%、58.33%、60.00%、40.00%、50.00%和33.33%。结论   CE是一种安全、有效的小肠疾病诊断工具，对小肠疾病具有较高的检出价值，但CE对慢性腹痛、腹胀、腹泻等非特异性消化道症状的诊断价值有待进一步评估。

Abstract:

Objective To explore the detection value of capsule endoscopy (CE) for small bowel disease and assess its security. Methods Clinical data of 142 patients received CE were analyzed retrospectively, symptomatic group (124 cases) and control group (18 cases). Run-time of CE, intestinal cleanliness, lesion detection and complications were analyzed, then assess CE detection value for intestinal disease and its security. Results All the patients have not shown swallowed trachea, capsule retention and other complications. The average running time is 498.3 min, including stomach average running time 35.6 min and small intestine average running time 273.6 min. The overall detection rate for intestinal diseases is 57.14 % and detection rate in symptomatic group is 59.68 %, detection rate in control group was 37.50%. The intestinal disease detection rate for symptomatic group is significantly higher than control group, which the difference was statistically significant (P < 0.05). In symptomatic group, the detection rate of CE in detection for obscure gastrointestinal bleeding, abdominal pain, diarrhea patients, abdominal distension, weight loss/anorexia patients, elevated tumor markers and abnormal bowel movements cases were 78.38 %, 52.08 %, 58.33 %, 60.00 %, 40.00 %, 50.00 % and 33.33 % respectively. Conclusions CE is a safe and effective diagnostic tool for intestinal diseases and it has a high detection value for intestinal diseases. The diagnostic value of chronic abdominal pain, bloating, diarrhea and other non-specific gastrointestinal symptoms should be further assessed.